
β-Herpesviruses in Febrile Children with Cancer

Stephanie Yee-Guardino,* Kate Gowans,* Belinda Yen-Lieberman,† Pamela Berk,† Debra Kohn,† Fu-Zhang Wang,†¹ Lara Danziger-Isakov,*† Camille Sabella,*† Sarah Worley,† Philip E. Pellett,†² and Johanna Goldfarb*†

We conducted a cross-sectional study of β-herpesviruses in febrile pediatric oncology patients (n = 30), with a reference group of febrile pediatric solid-organ transplant recipients (n = 9). One (3.3%) of 30 cancer patients and 3 (33%) of 9 organ recipients were PCR positive for cytomegalovirus. Four (13%) of 30 cancer patients and 3 (33%) of 9 transplant recipients had human herpesvirus 6B (HHV-6B) DNAemia, which was more common within 6 months of initiation of immune suppression (4 of 16 vs. 0 of 14 cancer patients; p = 0.050). HHV-6A and HHV-7 were not detected. No other cause was identified in children with HHV-6B or cytomegalovirus DNAemia. One HHV-6B-positive cancer patient had febrile disease with concomitant hepatitis. Other HHV-6B-positive children had mild "viral" illnesses, as did a child with primary cytomegalovirus infection. Cytomegalovirus and HHV-6B should be included in the differential diagnosis of febrile disease in children with cancer.

Much remains to be learned about the pathogenic role of β-herpesviruses (cytomegalovirus [CMV], human herpesvirus 6 variants A and B [HHV-6A and HHV-6B], and human herpesvirus 7 [HHV-7]) in immune-compromised children. Most persons are infected with CMV, HHV-6B, and HHV-7 during childhood; the age of acquisition and clinical spectrum of HHV-6A have not been defined. In immune-competent children, CMV is associated with heterophile-negative mononucleosis, HHV-6B with roseola infantum (exanthem subitum or sixth disease), and HHV-7 with a small percentage of clinically recognized cases of roseola. However, most primary infections with these viruses are either asymptomatic or involve a nonspecific mild illness that can include fever, malaise, and abnormal liver function or hepatosplenomegaly (1–4). After primary infection, these viruses establish life-long residency

*Cleveland Clinic Children's Hospital, Cleveland, Ohio, USA; and †Cleveland Clinic, Cleveland, Ohio, USA

in the host, seldom causing disease unless the immune system is weakened, as occurs after treatment for solid-organ and stem cell transplantation. In these patients, each of the β-herpesviruses can reactivate, manifesting as febrile and sometimes life-threatening illness including pneumonitis, encephalitis, bone marrow suppression, graft-versus-host disease, and organ rejection (5–7). In addition to having independent pathologic effects, β-herpesviruses may have additive or synergistic effects, as well as interactions with other infectious agents (e.g., fungal infections) (8,9).

Immune suppression caused by cancer treatment has many forms, often as pulses of cytotoxic agents that kill rapidly dividing cells, including lymphocytes. The risk for infections in pediatric cancer patients is well recognized, and much effort has been devoted to identifying and treating bacterial and fungal infections associated with fever and neutropenia (10–14). This effort usually involves hospitalization for empiric administration of intravenous antimicrobial drugs, even though most bacterial blood cultures remain negative; 40%–70% of such febrile episodes have no identifiable source (15,16). Some viral infections, such as those with herpes simplex or varicella zoster viruses, are associated with disease that can be serious and even fatal in pediatric oncology patients (17,18). Most episodes of fever are unexplained and assumed to be viral in nature (19).

Little attention has been paid to the possible contribution of β-herpesviruses as a cause of febrile illness in children with cancer, despite recognition that these viruses cause disease after organ transplantation. In studies that preceded application of PCR, CMV detection was associated with fever and hepatitis in children with malignancy

¹Current affiliation: University of North Carolina, Chapel Hill, North Carolina, USA

²Current affiliation: Wayne State University School of Medicine, Detroit, Michigan, USA

(20,21). HHV-6 seroprevalence is similar in pediatric cancer patients and controls (22,23), but virus has been detected less frequently in saliva of children with cancer than that of healthy controls (24). In children from the Czech Republic, Michalek et al. detected both primary and reactivated HHV-6 and CMV infections during cytotoxic chemotherapy by using serologic analysis and PCR (23,25). Some HHV-6 infections were associated with severe disease, including pneumonitis, bone marrow aplasia, and persisting fever.

Because of the biologic plausibility of β -herpesvirus involvement in febrile illness in pediatric cancer patients and the paucity of PCR-era literature in this area, we conducted a cross-sectional study of the activity of these viruses in pediatric cancer patients and other immune-compromised children. The purpose of this study was to determine whether there is sufficient viral activity in these populations to warrant in-depth study and clinical consideration.

Materials and Methods

Patients

The study was reviewed and approved by the Cleveland Clinic Institutional Review Board. Informed consent was obtained from a parent or guardian of each person <18 years of age, or directly from persons ≥ 18 years of age; assent was obtained from children 7–17 years of age. Patients were enrolled from August 2004 through April 2005. Enrolled children were receiving treatment for a malignancy or were receiving immunosuppressive therapy after solid-organ transplantation (SOT). Inclusion criteria were an age of newborn to 21 years and new onset of fever with an oral or rectal temperature $\geq 38^\circ\text{C}$ or an axillary temperature $\geq 37.5^\circ\text{C}$. At enrollment, we collected a blood specimen and information on age, sex, underlying illness and diagnosis, acute symptoms accompanying fever, and details about immune suppression (chemotherapy regimen, radiation therapy, immune modulators, and steroids). Gastrointestinal symptoms were defined as either vomiting or diarrhea. Clinical laboratory data collected included complete blood counts, renal and liver function test results, bacterial blood cultures, as well as results of testing conducted for evaluation of fever, such as respiratory virus analysis, stool studies, chest radiographs, and computed tomography scans.

Specimens and Storage

Whole blood was collected in EDTA tubes and stored at 4°C until processed. A leukocyte pellet was collected from 1 mL of whole blood; 400 μL of plasma was preserved, 200 μL for PCR and 200 μL for serologic analysis. Pelleted leukocytes were added to MagnaPure LC lysis buffer (Roche Diagnostics, Indianapolis, IN, USA) and stored at -20°C .

Virus Culture

CMV culture was conducted with pelleted leukocytes by using conventional MRC-5 cell shell vial cultures (Diagnostic Hybrids, Athens, OH, USA). Immune fluorescence testing was conducted after 48 hours by using a monoclonal antibody directed against the CMV immediate early protein (Chemicon, Temecula, CA, USA). Shell vial cultures were obtained for the first 11 patients enrolled; all cultures were negative. Because shell vial culture uses a large number of leukocytes and we were studying a neutropenic population, this procedure was discontinued to preserve cells for more sensitive PCR analysis (26). Purified lymphocytes were cultured to detect HHV-6 or HHV-7 infections as described (27,28). Cytopathic effect was recognized as enlarged and refractile cells, with confirmatory testing by PCR.

Polymerase Chain Reaction

Template DNA was extracted by using the MagnaPure automated extraction method (Roche Diagnostics) and eluted into 50 μL of buffer. A total of 5 μL of eluted DNA was used in each PCR. The PCRs contained DNA extracted from the equivalent of ≈ 20 μL of plasma, leukocytes present in 100 μL of whole blood, and 20 μL of whole blood. For detection of CMV and HHV-6 variants A and B, the Artus CMV RG PCR ASR/Real Art/Qiagen RealArt CMV LC Assay and the RealArt/Qiagen HHV-6 A/B LC Assay (QIAGEN, Hamburg, Germany) were used. A co-amplified internal control was used to identify PCR inhibition. To differentiate between HHV-6 variants, the system uses the specific melting temperatures of the probes. Detection of HHV-7 was conducted by using previously described primers and hybridization probes (29). Real-time PCR was performed on a LightCycler system (Roche Diagnostics).

Serologic Analysis

CMV serologic analysis was performed by using the VIDAS CMV IgG Assay (bioMérieux, Durham, NC, USA) in an automated instrument, according to the manufacturer's protocol. Analyses for HHV-6 (using HHV-6A-infected cells) and HHV-7 were conducted by using conventional indirect immunofluorescence with commercial slides (Panbio Ltd, Columbia, MD, USA). Avidity of antibody to HHV-6 was tested as described by Ward et al. (30).

Statistical Analysis and Clinical Associations

The exact unconditional test was used to compare groups on viral activity (31). All tests were 2-tailed and performed at a significance level of 0.05. Analyses were performed by using StatXact PROCs version 6.3 (Cytel Software Corp., Cambridge, MA, USA) and SAS version 9.1 (SAS Institute Inc., Cary, NC, USA). Clinical associations with β -herpesvirus infection were based on symptoms

and concomitant laboratory findings in patients who had no other identifiable cause for their febrile illness.

Results

Patient Characteristics

Forty-one children were enrolled, from whom 39 evaluable specimens were available (Table 1). Thirty of the 39 children had a malignancy (our primary interest) and 9 were organ transplant recipients who were included for comparison. All cancer patients were receiving active therapy, except for 1 child who was included in the study because she had been receiving chemotherapy for 2.5 years, which ended 3 months before study enrollment. Several patients had symptoms in addition to fever, mostly upper respiratory or gastrointestinal. A source of fever was identified for 5 (17%) of 30 cancer patients and 2 (22%) of 9 organ transplant recipients. Two cancer patients had bacteremia (*Escherichia coli*, coagulase-negative staphylococci); no fungal infections were detected. Three cancer patients and 2 organ transplant recipients had respiratory viral infections diagnosed by symptoms and positive direct fluorescent antibody test results. Of the 39 children, levels of liver enzymes were obtained for 28 as part of routine care. Of these children, 6 had abnormal values; 2 of these 6 also had virus detected (HHV-6B in 1 patient and influenza A in the other). The other 4 patients with increased levels of liver enzymes had longstanding abnormalities; review of their records suggested that the abnormal results were caused by underlying disease in 1 liver transplant patient and chemotherapy in 3 cancer patients. Six patients have died since completion of our study, none from infectious causes.

Laboratory Results

Of the 11 specimens tested in the shell vial assay, none was positive for CMV. CMV DNA was detected by PCR in lymphocytes of 1 (3.3%) of 30 cancer patients and 3 (33%) of 9 organ transplant recipients (Table 2).

Lymphocyte cultures for HHV-6 and HHV-7 were obtained for 34 of the 39 children. Of these, 15 cultures showed cytopathic effects similar to those commonly reported for HHV-6, but none of these were positive for HHV-6 by PCR. Cultured cells from 1 patient with leukemia (study participant 19) were positive for HHV-6B by PCR, in the absence of a cytopathic effect. Four (13%) of 30 cancer patients and 3 (33%) of 9 transplant recipients (p = 0.19) had HHV-6B DNAemia; HHV-6A was not detected. Viral loads ranged from 50 to 500,000 DNA copies/mL. Of 7 PCR-positive patients, 3 also showed positive results in peripheral blood mononuclear cells (PBMC) and whole blood specimens, 2 in only PBMC, and 1 only in a lymphocyte culture. Patient 40, a transplant recipient, had positive results in all specimens tested including PBMC, whole

Table 1. Characteristics of febrile immune-suppressed children*

Characteristic	Cancer (n = 30)	SOT (n = 9)
Age, y; mean, median, range	6.1, 5.0, 0.4–17	11.8, 13.3, 4.3–20.6
Sex		
F	14	7
M	16	2
Basis of immune suppression		
Cancer	30 (77%)	–
Solid tumor	20	–
Leukemia	9	–
Lymphoma	1	–
Solid-organ transplant	–	9 (23%)
Heart	–	5
Lung	–	2
Liver	–	2
Immune suppressants	29	9
Cytotoxic chemotherapy	28	–
Radiation	6	–
Chemotherapy and radiation	6	–
Immune modulators†	–	9
Steroids (past 6 months)	14	7
Signs and symptoms		
Ill appearance	7	1
Upper respiratory	17	1
Gastrointestinal	10	7
Headache	3	3
Rash	0	0
Seizure	0	0
Hepatitis	1	1
Blood products (past 6 months)‡	20	5
Laboratory parameters		
Neutropenic (<500 cells/μL)	14	2
Lymphopenic (<500 cells/μL)	13	4
Established source for fever		
Bacteremia	2	0
Positive respiratory DFA test result§	3	2

*SOT, solid-organ transplantation; –, not applicable; DFA, direct fluorescence antigen.

†Immune modulators included tacrolimus in 4, tacrolimus and azathioprine in 2, cyclosporine and mycophenolate mofetil in 2, sirolimus in 1, and tacrolimus, mycophenolate mofetil, antithymocyte globulin (rabbit), and corticosteroids in 1.

‡Blood products recorded included packed erythrocytes or platelets.

§Of the 5 patients with positive respiratory DFA test results, 2 were positive for parainfluenza 3, 2 for influenza A, and 1 for respiratory syncytial virus.

blood, and plasma, with the highest viral load (>5 × 10⁵ genomes/mL) in PBMC. These results are consistent with either severe acute infection or the child having germline integrated HHV-6B (32,33). PCR positivity was more common in children whose blood was collected within 6 months of initiation of immune suppression compared with children sampled >6 months after initiation of immune suppression (cancer patients: 4 of 16 vs. 0 of 14 after 6 months, p = 0.050; transplant recipients: 2 of 3 vs. 1 of 6, p = 0.26) (Figure). Solid-tumor patients were less likely to be positive for HHV-6B than either leukemic (1 of 20 vs. 3 of 9,

Table 2. Detection of β -herpesviruses in cancer patients and solid-organ transplant recipients*

Characteristic	Cancer patients, no. positive/no. tested (%)		Transplant patients (n = 9), no. positive/no. tested (%)
	Leukemia (n = 9)	Solid tumor (n = 20)	
CMV PCR			
Whole blood	1/6 (17)	0/5	3/7 (43)
PBMC	1/7 (14)	0/16	2/8 (25)
Plasma	0/9	0/20	2/9 (22)
All tests	1/9 (11)	0/20 (0)	3/9 (33)
HHV-6 PCR			
Whole blood	2/6 (33)	0/5	2/7 (29)
PBMC	1/7 (14)	1/16 (6)	3/8 (38)
Plasma	0/9	0/19	1/9 (11)
Lymphocyte culture	1/8 (13)	0/16	0/9
All tests	3/9 (33)	1/20 (5)	3/9 (33)
HHV-7 PCR			
Whole blood	0/6	0/5	0/7
PBMC	0/7	0/16	0/8
Plasma	0/9	0/20	0/9
All tests	0/9	0/20	0/9

*Data are not shown for study participant 23, a patient with lymphoma who did not have β -herpesviruses detected in whole blood, PBMC, or plasma. CMV, cytomegalovirus; PBMC, peripheral blood mononuclear cells; HHV-6, human herpesvirus 6.

$p = 0.046$) or SOT patients (1 of 20 vs. 3 of 9, $p = 0.046$). Two of the HHV-6B-positive SOT patients had concurrent CMV DNAemia.

HHV-7 DNA was not detected in any patients. Lymphocyte cultures were not tested for HHV-7 by PCR because none of the plasma, whole blood, or leukocyte pellets were positive for the virus.

Possible Associations between β -Herpesvirus Activity and Disease

Patients who were positive for β -herpesviruses and those who were negative for these viruses did not differ in their average fever temperature (38.5°C vs. 38.6°C). In SOT recipients, the prevalence of HHV-6B and CMV and the spectrum of their associated illnesses were concordant with prior reports. Thus, we will focus on the cancer patients.

The only cancer patient with CMV DNAemia appeared to have primary CMV infection on the basis of negative results for immunoglobulin (Ig) G to CMV, negative bacterial blood culture, and age (online Appendix Table, available from www.cdc.gov/EID/content/14/4/579-appT.htm). This patient was a 5.4-year-old child (study participant 29) with acute lymphoblastic leukemia (ALL) in remission; he had upper respiratory symptoms and fever but otherwise appeared well. He was treated with an antimicrobial drug (ceftriaxone) on an outpatient basis, but his blood culture was negative for bacteria and no other source for his fever and illness was found. This child began cancer chemotherapy 36 months before the febrile event.

Four patients appeared to have reactivated HHV-6B infection on the basis of positive results for virus DNA, high-avidity IgG, and clinical symptoms. The first patient (study participant 19) was a 2-year-old boy with ALL in

remission for the first time. In the second month of chemotherapy; he was hospitalized for fever and ill appearance, but he was not neutropenic or lymphopenic. He had marked hepatomegaly (≈ 10 cm below the right costal margin) and abnormal results in liver function tests. He was receiving fluconazole for oral thrush, and his liver enzyme levels were mildly increased before the febrile illness. However, at admission he had an aspartate aminotransferase (AST) level of 2,356 U/L and an alanine aminotransferase (ALT) level of 2,410 U/L. HHV-6 and HHV-7 IgM and IgG titers were obtained (Specialty Laboratories, Valencia, CA, USA) as part of his ALL treatment protocol. His HHV-6 IgM titer was negative (<40), and his IgG titer was positive (320) and high-avidity antibodies were detected. Results for HHV-7 IgM were negative, and those for IgG were weakly positive (titer 20). Other studies conducted by the primary medical team included tests for acute hepatitis and a CMV PCR; all results were negative. Four days later, his AST level was 84 U/L and his ALT level was 314 U/L. On follow up 7 days after admission, both values were near normal. The hepatitis was attributed to methotrexate, which was therefore withheld until the levels of liver enzymes returned to normal. On the basis of the positive culture for HHV-6B and hepatitis in the setting of febrile illness without other identified infections, we suspect that reactivated HHV-6B infection caused the fever and exacerbated the hepatitis.

A 5-year-old girl with relapsed acute myeloid leukemia (study participant 23) was intermittently febrile while hospitalized for 1 month during chemotherapy. She was treated with broad-spectrum antibacterial drugs and antifungal drugs. At study enrollment on day 12 of hospitalization, she had an absolute neutrophil count of 0 and an absolute lymphocyte count of 560 cells/ μL . Daily blood cultures and sporadic respiratory viral studies did not re-




Figure. Temporal relationship between detection of β-herpesvirus (βHV) and onset of immune suppression. Time of collection of each study specimen is indicated relative to onset of immune suppression for cancer patients and solid-organ transplant recipients. HHV, human herpesvirus; CMV, cytomegalovirus.

veal a cause for her fever, but her whole blood and PBMC were positive for HHV-6B by PCR.

HHV-6B was detected in a 2-year-old girl with ALL in remission (study participant 25) and in a 22-month-old boy with stage 3 Wilms tumor (study participant 38). Both of these patients were lymphopenic and had nonspecific febrile illnesses; neither had other identified sources of fever.

We suspect primary CMV infection in 1 patient and reactivated HHV-6B infection in 4 cancer patients as likely causes of the febrile episodes. This conclusion is based on a combination of clinical data, positive PCR findings, and lack of other identified sources for fever.

Discussion

β-Herpesviruses are known pathogens in immunocompromised patients, but they have not been extensively studied in children with malignancies. In this study of children who had fever, signs of infection, and had samples taken at 1 time point, we detected β-herpesviruses in 5 of 25 cancer patients who had no other source of fever identified: 4 had HHV-6B DNA and 1 had CMV DNA detected by PCR. β-Herpesviruses were detected in 4 of 7 SOT patients who had no other source of fever identified: 1 had HHV-6B, 1 had CMV, and 2 had both viruses (Figure). One of these children was ill and had a high fever and pleuritis with no other pathogens identified. HHV-6A and HHV-7 were not detected in any of the cancer or SOT patients. In our study, frequencies of HHV-6B were similar in transplant recipients and cancer patients (3 of 9 vs. 4 of 30, *p* = 0.19).

HHV-6B was detected more frequently in children with leukemia and solid-organ transplants than in children with other cancers. This finding may be the result of similarities in the degree and type of immune suppression. Children with leukemia and SOT patients generally receive intense initial immune suppression followed by a constant lower level of suppression. In contrast, solid-tumor patients generally receive monthly immune-suppressive treatments and seldom have prolonged lymphopenia. HHV-6B DNAemia

was more frequent in children sampled during the first 6 months of immune suppression when immune suppression is most intense, which is consistent with findings for pediatric bone marrow and solid-organ transplant recipients (34). Detection of HHV-6B early after initiation of therapy in patients with cancer (Figure) suggests that the presence of virus DNA may be related to intense immune suppression and not to random occurrence, which would not have clustered early in therapy.

Our observations of possible clinical associations with β-herpesvirus infection concur with those of Michalek et al. (23,25) of a cohort dating from 1993 to 1999. Our population included 1 child with suspected HHV-6 disease and hepatitis, which has been seen in association with HHV-6 activity after liver (35), renal (36), and stem cell transplantation (37).

In contrast to laboratory detection for CMV, testing for HHV-6 and HHV-7 DNA is often conducted by using in-house assays, which makes comparison across studies difficult. We used an assay for detecting HHV-6 DNA that is commercially available in Europe. This test was concordant with our in-house assay in detecting previously characterized HHV-6 isolates (D. Kohn et al., unpub. data). In addition to standardization of molecular testing, various methods for detecting HHV-6 during febrile episodes should be evaluated because some investigators have suggested that viral isolation by culture may be more useful in correlating active infection with clinical disease (38). Furthermore, reverse transcription-PCR can distinguish active replication from latency (39,40).

Several limitations are inherent to our cross-sectional study design. First, capturing data at single time points limits the ability to assess the temporality of the virologic burden in relation to disease. Second, although we found HHV-6B positivity during febrile events in 18% of our population, we do not have data during periods without fever and therefore cannot be certain that viremia is specifically associated with disease. The studies by Michalek et al. also included treatment-phase blood specimens that were obtained only during febrile illness or other clinical events suggestive of viral infection (23,25). Thus, activity of HHV-6 and other lymphotropic viruses during nonfebrile periods in this patient population remains unknown. We studied a heterogeneous patient population that included several types of cancer; the level of immune suppression varied widely. Finally, identification of possible causes of febrile episodes was limited by the assays we performed and the tests ordered by the primary medical team. Thus, we cannot exclude other viral pathogens such as human metapneumovirus or Epstein-Barr virus for which no testing was conducted.

Evidence for our suspected associations between HHV-6B and the febrile events includes 1) our use of

relatively small volumes of blood in the PCR analyses, which reduces the chance of detecting sporadic latently infected lymphocytes; 2) the temporal association of detection of HHV-6B with initiation of chemotherapy; and 3) a lack of other identified sources for the fever. With the exception of the transplant recipient with possible HHV-6B germline integration, HHV-6B or CMV are plausible causes of the febrile episode in every instance in which they were detected.

Our study differs from prior studies in that we assayed for all 4 β -herpesviruses and considered the timing of viral activity relative to the onset of immune suppression. We included solid-organ transplant patients as a reference for cancer patients, and excluded stem cell transplant patients, a population in whom reactivation of CMV and HHV-6 has been studied. By enrolling children with a variety of malignancies, we surveyed a diverse cancer population.

Although the number of patients we studied was small, CMV and HHV-6B are clearly active in pediatric cancer patients. The lack of other identified agents coincident with fever suggests that these viruses may cause febrile illness in this population. Our observations, combined with those of Michalek et al. (23,25), suggest that HHV-6B and CMV should be included in the differential diagnoses of febrile disease in children with cancer. Further investigation in this patient population is needed to clarify the role of β -herpesviruses in these febrile illnesses.

Acknowledgments

We thank the patients and their families and physicians and nursing staff in Pediatric Hematology and Oncology for their participation in and support of this project.

Dr Yee-Guardino is a consultant in pediatrics at the Cleveland Clinic. Her research interests include herpesvirus disease in immunocompromised children.

References

- Hall CB, Long CE, Schnabel KC, Caserta MT, McIntyre KM, Costanzo MA, et al. Human herpesvirus-6 infection in children. A prospective study of complications and reactivation. *N Engl J Med*. 1994;331:432–8.
- Hall CB, Caserta MT, Schnabel KC, McDermott MP, Lofthus GK, Carnahan JA, et al. Characteristics and acquisition of human herpesvirus (HHV) 7 infections in relation to infection with HHV-6. *J Infect Dis*. 2006;193:1063–9.
- Wreghitt TG, Teare EL, Sule O, Devi R, Rice P. Cytomegalovirus infection in immunocompetent patients. *Clin Infect Dis*. 2003;37:1603–6.
- Manfredi R, Calza L, Chiodo F. Primary cytomegalovirus infection in otherwise healthy adults with fever of unknown origin: a 3-year prospective survey. *Infection*. 2006;34:87–90.
- Pellett PE, Tipples GA. Human herpesviruses 6, 7, and 8. In: Murray PR, Baron EJ, Jorgenson JH, Pfaller MA, Tenover FC, White
- Yamanishi K, Mori M, Pellett PE. Human herpesviruses 6 and 7. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, et al., editors. *Fields virology*. Philadelphia: Lippincott Williams and Wilkins; 2007. p. 819–45.
- Mocarski ES, Shenk T, Pass RF. Cytomegaloviruses. In: Knipe DM, Howley PM, Griffin DE, Lamb RA, Martin MA, Roizman B, et al., editors. *Fields virology*. Philadelphia: Lippincott Williams and Wilkins; 2007. p.2701–72.
- Wang FZ, Pellett PE. Human herpesviruses 6A, 6B, and 7: immunobiology and host response. In: Arvin A, Campadelli-Fiume G, Mocarski ES, Roizman B, Whitley RJ, Yamanishi K, editors. *Human herpesviruses: biology, therapy, and immunoprophylaxis*. Cambridge (UK): Cambridge University Press; 2006. p. 850–74.
- Singh N. Human herpesviruses-6, -7 and -8 in organ transplant recipients. *Clin Microbiol Infect*. 2000;6:453–9.
- Quezada G, Sunderland T, Chan KW, Rolston K, Mullen CA. Medical and non-medical barriers to outpatient treatment of fever and neutropenia in children with cancer. *Pediatr Blood Cancer*. 2007;48:273–7.
- Ozkaynak MF, Krailo M, Chen Z, Feusner J. Randomized comparison of antibiotics with and without granulocyte colony-stimulating factor in children with chemotherapy-induced febrile neutropenia: a report from the Children's Oncology Group. *Pediatr Blood Cancer*. 2005;45:274–80.
- Sung L, Feldman BM, Schwaborn G, Paczesny D, Cochrane A, Greenberg ML, et al. Inpatient versus outpatient management of low-risk pediatric febrile neutropenia: measuring parents' and healthcare professionals' preferences. *J Clin Oncol*. 2004;22:3922–9.
- Alexander SW, Wade KC, Hibberd PL, Parsons SK. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. *J Pediatr Hematol Oncol*. 2002;24:38–42.
- Castagnola E, Paola D, Giacchino R, Viscoli C. Clinical and laboratory features predicting a favorable outcome and allowing early discharge in cancer patients with low-risk febrile neutropenia: a literature review. *J Hematother Stem Cell Res*. 2000;9:645–9.
- Pizzo PA, Robichaud KJ, Wesley R, Commers JR. Fever in the pediatric and young adult patient with cancer. A prospective study of 1001 episodes. *Medicine (Baltimore)*. 1982;61:153–65.
- Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. *N Engl J Med*. 1986;315:552–8.
- Wood DJ, Corbett G. Viral infections in childhood leukemia. *J Infect Dis*. 1985;152:266–73.
- Christensen MS, Nielsen LP, Hasle H. Few but severe viral infections in children with cancer: a prospective RT-PCR and PCR-based 12-month study. *Pediatr Blood Cancer*. 2005;45:945–51.
- Wood MJ. Viral infections in neutropenia—current problems and chemotherapeutic control. *J Antimicrob Chemother* 1998;41(Suppl D):81–93.
- Furukawa T, Funamoto Y, Ishida S, Kamiya H. The importance of primary cytomegalovirus infection in childhood cancer. *Eur J Pediatr*. 1987;146:34–7.
- Rokicka-Milewska R, Pacholska J, Lukowska K, Paciorkiewicz W, Jastrzebska M. Cytomegalovirus infection in children with blood diseases. *Acta Haematol Pol*. 1992;23:191–5.
- Lyll EG. Serological response of paediatric oncology patients to human herpesvirus-6. *J Med Virol*. 1994;43:373–9.
- Michalek J, Horvath R, Benedik J, Hrstkova H. Human herpesvirus-6 infection in children with cancer. *Pediatr Hematol Oncol*. 1999;16:423–30.
- Lyll EG, Cubie HA. Human herpesvirus-6 DNA in the saliva of paediatric oncology patients and controls. *J Med Virol*. 1995;47:317–22.
- Michalek J, Horvath R. High incidence of Epstein-Barr virus, cytomegalovirus and human herpesvirus 6 infections in children with cancer. *BMC Pediatr*. 2002;2:1.

26. Caliendo AM, Yen-Lieberman B, Baptista J, Andersen J, Crumpacker C, Schuurman R, et al. Comparison of molecular tests for detection and quantification of cell-associated cytomegalovirus DNA. *J Clin Microbiol.* 2003;41:3509–13.
27. Black JB, Burns DA, Goldsmith CS, Feorino PM, Kite-Powell K, Schinazi RF, et al. Biologic properties of human herpesvirus 7 strain SB. *Virus Res.* 1997;52:25–41.
28. Black JB, Sanderlin KC, Goldsmith CS, Gary HE, Lopez C, Pellett PE. Growth properties of human herpesvirus-6 strain Z29. *J Virol Methods.* 1989;26:133–45.
29. Safronetz D, Humar A, Tipples GA. Differentiation and quantitation of human herpesviruses 6A, 6B and 7 by real-time PCR. *J Virol Methods.* 2003;112:99–105.
30. Ward KN, Turner DJ, Parada XC, Thiruchelvam AD. Use of immunoglobulin G antibody avidity for differentiation of primary human herpesvirus 6 and 7 infections. *J Clin Microbiol.* 2001;39:959–63.
31. Suissa S, Shuster JJ. Exact unconditional sample sizes for the 2×2 binomial trial. *Journal of the Royal Statistical Society A.* 1985;148:317–27.
32. Leong HN, Tuke PW, Tedder RS, Khanom AB, Eglin RP, Atkinson CE, et al. The prevalence of chromosomally integrated human herpesvirus 6 genomes in the blood of UK blood donors. *J Med Virol.* 2007;79:45–51.
33. Ward KN, Leong HN, Thiruchelvam AD, Atkinson CE, Clark DA. Human herpesvirus 6 DNA levels in cerebrospinal fluid due to primary infection differ from those due to chromosomal viral integration and have implications for diagnosis of encephalitis. *J Clin Microbiol.* 2007;45:1298–304.
34. Yoshikawa T. Human herpesvirus-6 and -7 infections in transplantation. *Pediatr Transplant.* 2003;7:11–7.
35. Griffiths PD, Ait-Khaled M, Bearcroft CP, Clark DA, Quaglia A, Davies SE, et al. Human herpesviruses 6 and 7 as potential pathogens after liver transplant: prospective comparison with the effect of cytomegalovirus. *J Med Virol.* 1999;59:496–501.
36. Ratnamohan VM, Chapman J, Howse H, Bovington K, Robertson P, Byth K, et al. Cytomegalovirus and human herpesvirus 6 both cause viral disease after renal transplantation. *Transplantation.* 1998;66:877–82.
37. Ljungman P, Wang FZ, Clark DA, Emery VC, Remberger M, Ringden O, et al. High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patients. *Br J Haematol.* 2000;111:774–81.
38. Yoshikawa T, Asano Y, Ihira M, Suzuki K, Ohashi M, Suga S, et al. Human herpesvirus 6 viremia in bone marrow transplant recipients: clinical features and risk factors. *J Infect Dis.* 2002;185:847–53.
39. Norton RA, Caserta MT, Hall CB, Schnabel K, Hocknell P, Dewhurst S. Detection of human herpesvirus 6 by reverse transcription-PCR. *J Clin Microbiol.* 1999;37:3672–5.
40. Yoshikawa T, Akimoto S, Nishimura N, Ozaki T, Ihira M, Ohashi M, et al. Evaluation of active human herpesvirus 6 infection by reverse transcription-PCR. *J Med Virol.* 2003;70:267–72.

Address for correspondence: Philip E. Pellett, Department of Immunology and Microbiology, Wayne State University School of Medicine, 540 E Canfield Ave, 6225 Scott Hall, Detroit, MI 48202, USA; email: ppellett@med.wayne.edu

EMERGING INFECTIOUS DISEASES

Full text free online at
www.cdc.gov/eid

The print journal is available at no charge to public health professionals

YES, I would like to receive Emerging Infectious Diseases.

Please print your name and business address in the box and return by fax to 404-639-1954 or mail to

EID Editor
CDC/NCID/MS D61
1600 Clifton Road, NE
Atlanta, GA 30333

Moving? Please give us your new address (in the box) and print the number of your old mailing label here _____

EID
Online
www.cdc.gov/eid

Appendix Table. Characteristics of cancer patients with suspected β -herpesvirus infection on the basis of DNAemia and clinical signs and symptoms*

Study no.	Interval, mo†	Clinical status	Age, y	Chemo-therapeutics	Symptoms in addition to fever	Fever duration, d	Pertinent physical findings	General appearance	AV	Pertinent laboratory values	Viral load (copies/mL)							
											HHV-6B				CMV			
											WB	PBMC	PL	LC	WB	PBMC	PL	LC
23	<1	AML recurrence‡	5	ARA-C, gemtuzumab, ozogamicin	Diarrhea	6	None	Well	None	ANC 0, ALC 560, high-avidity antibody to HHV-6	1,560	495	–	–	–	–	–	–
19	1	ALL in remission	2.1	Asparaginase, 6-MP, MTX, vincristine, decadron	URI	1	Hepatomegaly, red left tympanic membrane	Ill	None	AST 2,356, ALT 2,410, high-avidity antibody to HHV-6	NT	NT	–	685	NT	NT	–	–
25	2	ALL in remission	2.3	Daunorubicin, MTX, vincristine, ARA-C	None	1	None	Well	None	ANC 550, high-avidity antibody to HHV-6	58	–	–	NT	–	–	–	–
38	3	Wilms tumor	1.9	Actinomycin-D, vincristine	None	1	None	Well	None	ALC 530, high-avidity antibody to HHV-6	NT	97	–	NT	NT	–	–	NT
29	36	ALL in remission	5.4	6-MP, MTX	URI	1	None	Well	None	ALC 300, CMV IgG negative	–	–	–	–	26,300	25	–	–

*AV, antiviral therapy; HHV-6B, human herpesvirus 6B; CMV, cytomegalovirus; WB, whole blood; PMBC, peripheral blood mononuclear cells; PL, plasma; LC, lymphocyte culture, AML, acute myeloid leukemia; ARA-C = cytarabine, ANC, absolute neutrophil count in cells/ μ L; ALC, absolute lymphocyte count in cells/ μ L; ALL, acute lymphoblastic leukemia; 6-MP, 6-mercaptopurine; MTX, methotrexate; URI, upper respiratory infection; AST, aspartate aminotransferase in U/L; ALT, alanine aminotransferase in U/L; NT, not tested (i.e., specimen not available or equipment failure); IgG, immunoglobulin G.

†Time between fever and onset of immune suppression.

‡We describe this patient as immune suppressed for <1 mo. This patient originally was treated for AML and had ended therapy 12 months before study enrollment.